Key Highlights

  • Applied DNA Sciences rebranded as BNB Plus Corp in late 2025 while retaining its LineaRx nucleic-acid production subsidiary.
  • The company disclosed roughly $4.1 million in convertible preferred financing commitments and a $1.2 million LineaDNA order.
  • BNB Plus failed Nasdaq's $1.00 minimum bid-price requirement and is transitioning to the OTCQB Market pending a hearing review.

Few small-cap stories have changed shape as abruptly as the company now trading as BNB Plus Corp. (BNBX). The Business was known for years as Applied DNA Sciences, a DNA-manufacturing and biosecurity specialist, before reinventing itself around a Cryptocurrency treasury strategy tied to Binance's BNB token. Along the way its shares slipped off Nasdaq's main tier. A flat recent session gives the impression of calm, but the corporate story underneath has been anything but quiet, spanning a rebrand, fresh financing and a fight to preserve its exchange standing.

Company and Latest Development

BNB Plus Corp. is the rebranded successor to Applied DNA Sciences, a change unveiled in late 2025 as management pivoted toward a digital-asset treasury model centred on the BNB token. Crucially, the company did not abandon its scientific roots: it retains a biopharmaceutical and DNA/RNA production operation through its LineaRx subsidiary, which develops technologies to produce and detect nucleic acids for therapeutic and diagnostic uses. The transformation has been accompanied by boardroom change, including a new chairman, and by capital-raising activity. Reported developments include roughly $4.1 million in convertible preferred stock financing commitments, a $1.2 million LineaDNA order, and a board-authorised strategic review aimed at maximising Shareholder value. The result is an unusual hybrid: a legacy life-sciences platform bolted onto a crypto-treasury thesis.

What Is Driving Attention Around BNBX?

The most recent session was essentially flat, so there is no verifiable single-day catalyst behind the tape. Interest in BNBX instead reflects its dramatic repositioning and its listing troubles. The company failed to maintain Nasdaq's minimum $1.00 bid-price requirement, triggering a delisting determination; it has been transitioning to the OTCQB Market while seeking review by the Nasdaq Listing and Hearing Review Council. For a former Nasdaq biosecurity name to reinvent itself as a BNB-focused treasury vehicle is itself the story, rather than any confirmed price trigger on the quiet trading day.

Key Numbers and Company Position

The verifiable figures describe a distressed micro-cap. BNBX has recently traded around $0.15 per share, with a Market Capitalisation in the low seven figures, roughly $1 million to $1.2 million. For fiscal 2025 the company reported Revenue of about $2.14 million against a net loss of roughly $69.5 million, underscoring the scale of its operating losses relative to sales. It has disclosed about $4.1 million in convertible preferred financing commitments. The sub-$1 share price is central to its listing predicament and highlights how far the Equity has fallen from its former Nasdaq levels.

What Could Come Next?

Several company-specific items could shape sentiment. The outcome of the Nasdaq appeal and the mechanics of the OTCQB transition are immediate variables. Beyond listing status, investors may watch execution of the BNB treasury strategy, additional LineaRx or LineaDNA orders, and any conclusions from the board's strategic review. Given the loss profile, further financing looks likely, so any Capital raise, Partnership or asset sale would be material. Progress, or lack of it, on the crypto-treasury thesis could also swing perception of the stock.

Risks to Watch

The risks are substantial. Loss of a Nasdaq listing typically reduces Liquidity and institutional visibility. A treasury strategy anchored to a single Crypto Token exposes the company to sharp swings in BNB's price. Heavy net losses point to cash-burn and going-concern pressure, while convertible instruments raise the prospect of further dilution. Executing a dual life-sciences-and-crypto model is itself demanding, and micro-cap trading adds Volatility and thin liquidity.

Conclusion

BNB Plus Corp. enters late 2026 as a heavily transformed micro-cap: a former Nasdaq biosecurity firm now built around a BNB treasury thesis while retaining its LineaRx DNA operations. A quiet trading day masks a turbulent backdrop of rebranding, financing and a contested delisting. The developments worth monitoring are concrete: the Nasdaq review and OTCQB transition, treasury execution, LineaRx order flow, the strategic review, and future funding. For now, BNBX remains a high-risk, speculative situation where listing status and capital will likely dictate the narrative.